{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:18:04Z","timestamp":1780647484777,"version":"3.54.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"Saint Baldricks Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018758","name":"Pediatric Transplantation and Cellular Therapy Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jtct.2023.10.005","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T07:39:19Z","timestamp":1696923559000},"page":"56-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-1594","authenticated-orcid":false,"given":"Lena E.","family":"Winestone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Bhojwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ghorashian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison Barz","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8000-0179","authenticated-orcid":false,"given":"Angela","family":"Steineck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-5285","authenticated-orcid":false,"given":"Claudia","family":"R\u00f6ssig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Maude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-6767","authenticated-orcid":false,"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.10.005_bib0001","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.005_bib0003","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128013","article-title":"Successful treatment of chimeric antigen receptor T cell therapy in refractory or relapsed acute leukemia patients with TP53 alterations","volume":"134","author":"Qu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V122.21.56.56","article-title":"Characteristics and outcomes of patients with Down syndrome-associated acute lymphoblastic leukaemia treated on UKALL 2003","volume":"122","author":"Patrick","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2023.10.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10510","article-title":"Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): a Children's Oncology Group (COG) report","volume":"38","author":"Rabin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0007","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12348","article-title":"Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome","volume":"162","author":"Meyr","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0008","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/pbc.24918","article-title":"Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome","volume":"61","author":"Hitzler","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.10.005_bib0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.10.005_bib0010","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0011","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world Chimeric Antigen Receptor Consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0012","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0013","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"Moskop","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.005_bib0014","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","article-title":"Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia","volume":"36","author":"Laetsch","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108107","article-title":"Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia\u2014prospective open cohort analyses of the ALLR3 trial","volume":"9","author":"Masurekar","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2023.10.005_bib0016","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0017","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.10.005_bib0018","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"issue":"suppl1","key":"10.1016\/j.jtct.2023.10.005_bib0019","article-title":"Induction toxicities are more frequent in young adults compared to children treated on the Children's Oncology Group (COG) first relapse B-lymphoblastic leukemia clinical trial AALL1331","volume":"132","author":"Hogan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0020","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/pbc.26129","article-title":"Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed\/refractory acute lymphoblastic leukemia","volume":"63","author":"Sun","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.10.005_bib0021","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/s41375-022-01693-z","article-title":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL\u2014long-term follow-up from the prospective ALL-SCT 2003 trial","volume":"36","author":"Eichinger","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.005_bib0022","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group study [corrected]","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0023","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2021.03.034","article-title":"Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials","volume":"151","author":"Eckert","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtct.2023.10.005_bib0024","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.005_bib0025","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.10.005_bib0026","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.10.005_bib0027","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0028","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0029","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0030","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0031","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.2005.03.3373","article-title":"Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study","volume":"24","author":"Barredo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0032","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1991.9.1.145","article-title":"Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study","volume":"9","author":"Ochs","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0033","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2006.05.9055","article-title":"Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate","volume":"24","author":"Spiegler","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0034","doi-asserted-by":"crossref","first-page":"e29256","DOI":"10.1002\/pbc.29256","article-title":"Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: a report from the Children's Oncology Group study AALL02P2","volume":"68","author":"Hastings","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.10.005_bib0035","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.005_bib0036","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0037","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0038","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.005_bib0039","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.005_bib0040","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood-2016-03-704973","article-title":"Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia","volume":"128","author":"Irving","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0041","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.005_bib0042","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0043","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtct.2023.10.005_bib0044","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.005_bib0045","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0046","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0047","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.005_bib0048","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.2021013442","article-title":"Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia","volume":"139","author":"Chen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0049","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtct.2023.10.005_bib0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.21037\/tcr.2016.11.76","article-title":"Regulation of cytotoxic T-cell responses by p53 in cancer","volume":"5","author":"Braun","year":"2016","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.jtct.2023.10.005_bib0051","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0052","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood.2019004741","article-title":"A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial","volume":"136","author":"Tomizawa","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0053","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.005_bib0054","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2015.246","article-title":"Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol","volume":"30","author":"Driessen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.005_bib0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1542\/peds.63.1.80","article-title":"Thymic deficiency in Down's syndrome","volume":"63","author":"Levin","year":"1979","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtct.2023.10.005_bib0056","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41586-021-03929-x","article-title":"Blood and immune development in human fetal bone marrow and Down syndrome","volume":"598","author":"Jardine","year":"2021","journal-title":"Nature"},{"issue":"suppl1","key":"10.1016\/j.jtct.2023.10.005_bib0057","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/blood-2021-148967","article-title":"Blinatumomab associated seizure risk in patients with Down syndrome and B-lymphoblastic leukemia: an interim report from Children's Oncology Group (COG) study AALL1731","volume":"138","author":"Li","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0058","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/hematology.2019000009","article-title":"Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?","volume":"2019","author":"Muffly","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2023.10.005_bib0059","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock W","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2023.10.005_bib0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/bloodadvances.2017014944","article-title":"Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study","volume":"2","author":"Muffly","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.005_bib0061","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.005_bib0062","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.005_bib0063","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2020003482","article-title":"Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia","volume":"6","author":"Grover","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.005_bib0064","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.10.005_bib0065","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ajh.26853","article-title":"Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"9","author":"Aldoss","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0066","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.005_bib0067","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.10.005_bib0068","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0069","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","volume":"4","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jtct.2023.10.005_bib0070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/pbc.24233","article-title":"PROMIS pediatric measures in pediatric oncology: valid and clinically feasible indicators of patient-reported outcomes","volume":"60","author":"Hinds","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.10.005_bib0071","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jnci\/djaa016","article-title":"Validity and reliability of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events","volume":"112","author":"Reeve","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtct.2023.10.005_bib0072","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2020.2861","article-title":"Agreement between child self-report and caregiver-proxy report for symptoms and functioning of children undergoing cancer treatment","volume":"174","author":"Mack","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jtct.2023.10.005_bib0073","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jpainsymman.2014.12.010","article-title":"Feasibility of conducting a palliative care randomized controlled trial in children with advanced cancer: assessment of the PediQUEST study","volume":"49","author":"Dussel","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jtct.2023.10.005_bib0074","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2013.51.5981","article-title":"Improving the care of children with advanced cancer by using an electronic patient-reported feedback intervention: results from the PediQUEST randomized controlled trial","volume":"32","author":"Wolfe","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0075","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1002\/cncr.30782","article-title":"Voices of children and adolescents on phase I or phase II cancer trials: a new trial endpoint?","volume":"123","author":"Hinds","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.10.005_bib0076","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.33617","article-title":"Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy","volume":"127","author":"Leahy","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.10.005_bib0077","doi-asserted-by":"crossref","first-page":"e802","DOI":"10.1097\/HS9.0000000000000802","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a scoping review","volume":"6","author":"Efficace","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2023.10.005_bib0078","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.3390\/cancers14112742","article-title":"Longitudinal collection of patient-reported outcomes and activity data during CAR-T therapy: feasibility, acceptability, and data visualization","volume":"14","author":"Oswald","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2023.10.005_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.10.005_bib0080","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0081","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.10.005_bib0082","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.10.005_bib0083","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1002\/cncr.29597","article-title":"Symptom profiles in children with advanced cancer: patient, family caregiver, and oncologist ratings","volume":"121","author":"Zhukovsky","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.10.005_bib0084","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jpainsymman.2021.12.009","article-title":"Normalization of symptoms in advanced child cancer: the PediQUEST-response case study","volume":"63","author":"Requena","year":"2022","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jtct.2023.10.005_bib0085","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.10.005_bib0086","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/CCI.21.00023","article-title":"Next-generation implementation of chimeric antigen receptor T-cell therapy using digital health","volume":"5","author":"Banerjee","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.jtct.2023.10.005_bib0087","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2022-0037","article-title":"Barriers and solutions to improve access for chimeric antigen receptor therapies","author":"Kamal-Bahl","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtct.2023.10.005_bib0088","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/bmt.2015.246","article-title":"Geographic access to hematopoietic cell transplantation services in the United States","volume":"51","author":"Delamater","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.10.005_bib0089","unstructured":"Zamecnik A. Access to CAR-T therapies in Central and Eastern Europe in \u201ccatch-up\u201d mode compared to the West. Pharmaceutical Technology. April 29, 2022. Available at: https:\/\/www.pharmaceutical-technology.com\/features\/access-to-car-t-therapies-in-central-and-eastern-europe-in-catch-up-mode-compared-to-the-west\/. Accessed July 26, 2023."},{"key":"10.1016\/j.jtct.2023.10.005_bib0090","unstructured":"Osterwell N. Hidden costs of CAR T-cell therapy. Medscape. February 21, 2020. Available at: https:\/\/www.medscape.com\/viewarticle\/925543?form=fpf. Accessed July 26, 2023."},{"key":"10.1016\/j.jtct.2023.10.005_bib0091","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtct.2021.01.014","article-title":"Chimeric antigen receptor T cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration","volume":"27","author":"Alexander","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.10.005_bib0092","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.seminhematol.2023.01.001","article-title":"Place of care manufacturing of chimeric antigen receptor cells: opportunities and challenges","volume":"60","author":"Orentas","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0093","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jtct.2022.02.017","article-title":"Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma","volume":"28","author":"Kedmi","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.10.005_bib0094","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.10.005_bib0095","unstructured":"Baggott C, Kunicki M, Prabhu S, et al. Inferior outcomes among Black patients with childhood acute lymphoblastic leukemia following tisagenlecleucel. Presented at: Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. February 8-12, 2021. Available at: https:\/\/tct.confex.com\/tandem\/2021\/meetingapp.cgi\/Paper\/18094. Accessed August 28, 2023."},{"key":"10.1016\/j.jtct.2023.10.005_bib0096","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.005_bib0097","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.005_bib0098","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.2022017866","article-title":"Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy","volume":"141","author":"Newman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.005_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.022","article-title":"Access to chimeric antigen receptor T cell clinical trials in underrepresented populations: a multicenter cohort study of pediatric and young adult acute lymphobastic leukemia patients","volume":"29","author":"Hall","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2023.10.005_bib0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jtct.2023.08.007","article-title":"Assessing Medicaid coverage for hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy: a project from the ASTCT-NMDP ACCESS Initiative","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.10.005_bib0101","article-title":"Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries","volume":"10","author":"Canales Albendea","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtct.2023.10.005_bib0102","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1470-2045(19)30466-8","article-title":"Medical crowdfunding to access CAR T-cell therapy","volume":"20","author":"Ho","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:11:34Z","timestamp":1763003494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723015865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2666636723015865"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.10.005","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}